Skip to main
CNTA

CNTA Stock Forecast & Price Target

CNTA Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Centessa Pharmaceuticals has shown promising advancements in its ORX750 development for Sleep Disorders, which has led to a reassessment of its revenue forecast and expectations for market penetration in the orexin agonist space. With a strong financial position, evident from approximately $405 million in cash reserves supporting operations into mid-2027, the company is well-positioned to capitalize on future data and developments in its pipeline. Moreover, the expected commercialization of its innovative products, including major market expansion potential within a narcolepsy market currently valued at around $2.5 billion, reflects a robust outlook for Centessa Pharmaceuticals.

Bears say

Centessa Pharmaceuticals PLC faces significant commercial, competitive, and reimbursement risks that could hamper the market potential of its pipeline assets. The company's analysis indicates that its current valuation reflects a minimal market penetration expectation, which disregards the growth potential of key assets like ORX750, further exacerbating the financial outlook. Additionally, potential delays in clinical trials, safety concerns, and uncertain patent protections contribute to a heightened risk profile that may lead to downward revisions in the company’s valuation.

CNTA has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Centessa Pharmaceuticals PLC (CNTA) Forecast

Analysts have given CNTA a Buy based on their latest research and market trends.

According to 10 analysts, CNTA has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Centessa Pharmaceuticals PLC (CNTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.